(Q36570565)

15 August 2017

1 reference

title

The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation (English)

1 reference

15 August 2017

main subject

organ transplantation

1 reference

Joseph F Magliocca

1

1 reference

15 August 2017

Stuart J Knechtle

series ordinal

2

1 reference

15 August 2017

language of work or name

1 reference

1 September 2006

1 reference

15 August 2017

published in

Transplant International

1 reference

15 August 2017

volume

19

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

705-714

1 reference

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

The use of Campath-1H as induction therapy in renal transplantation: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Campath-1H in renal transplantation: The University of Wisconsin experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

The impact of Campath 1H induction in adult liver allotransplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Exfoliative rejection after intestinal transplantation in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Intestinal transplantation in children: a summary of clinical outcomes and prognostic factors in 108 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

Reversal of acute cellular rejection after renal transplantation with Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00343.X

10.1111/J.1432-2277.2006.00343.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference